Appointment dossier — Intracranial Sarcoma

Compounds studied in Intracranial Sarcoma

• Carboplatin — Human evidence · 2 positive · PMID 37508972, 26588458
• Etoposide — Human evidence · 2 positive · PMID 37508972, 26588458
• Ifosfamide — Human evidence · 2 positive · PMID 37508972, 26588458

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT05969860 · Phase 2 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer (United States)
• NCT06641908 · Phase 1 — Anti-GD2 ADC M3554 in Advanced Solid Tumors (United States)
• NCT06926283 · Phase 1 — A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (China)
• NCT06103669 — Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) (United States)
• NCT06506838 · Phase 4 — Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma (China)
• NCT06699472 · Phase 2 — A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib (China)
• NCT06650514 · Phase 2 — A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma (Spain)
• NCT03138161 · Phase 1 / Phase 2 — SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma (United States)
• NCT05641428 · Phase 2 — Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL (Netherlands)
• NCT06113809 · Phase 1 — Palbociclib and Pembrolizumab in Sarcoma (United States)
• NCT07211737 · Phase 1 — NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (United States)
• NCT07121946 · Phase 1 — This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (United States)
• NCT04986748 — Using QPOP to Predict Treatment for Sarcomas and Melanomas (Singapore)
• NCT05917301 — Pre-operative Hypofractionated Proton Therapy (United States)
• NCT07276867 — Intrathecal Dexmedetomidine-Fentanyl Combination Versus Fentanyl Alone as Adjuvant to Bupivacaine in Spinal Anesthesia for Above Knee Amputation in Sarcomas of Lower Extremity (Egypt)
• NCT04498767 — Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) (Belgium)
• NCT02701153 — Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort (United States)
• NCT03449264 — Development of Clinical and Biological Database (France)

Most-relevant first: trials that name Intracranial Sarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Carboplatin has been studied in people for Intracranial Sarcoma — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Etoposide has been studied in people for Intracranial Sarcoma — what's the evidence, and is it an option or available in a trial for me?
3. I've read that Ifosfamide has been studied in people for Intracranial Sarcoma — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT05969860), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?